Trial Profile
PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY NK/T-CELL LYMPHOMA
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Lenalidomide (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
- 21 Feb 2017 New trial record